MBRX Stock Overview
Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Moleculin Biotech, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$4.63 |
52 Week High | US$15.75 |
52 Week Low | US$4.28 |
Beta | 1.85 |
1 Month Change | -16.43% |
3 Month Change | -36.49% |
1 Year Change | -58.70% |
3 Year Change | -91.21% |
5 Year Change | -96.13% |
Change since IPO | -99.36% |
Recent News & Updates
Recent updates
We're A Little Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Rate
Dec 20Can Moleculin Biotech (NASDAQ:MBRX) Afford To Invest In Growth?
Jul 14Is Moleculin Biotech (NASDAQ:MBRX) In A Good Position To Deliver On Growth Plans?
Feb 18Here's Why We're Watching Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation
Nov 01Moleculin Biotech rises 7% as WP1096 compound selected for NIAID-funded animal studies
Sep 27Moleculin brain cancer therapy WP1122 gets FDA orphan drug status
Sep 06Here's Why We're Not Too Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation
Jul 11Moleculin potential COVID drug WP1122 shows safety in preliminary data from phase 1a trial
Jul 08We Think Moleculin Biotech (NASDAQ:MBRX) Can Afford To Drive Business Growth
Mar 28We're Not Very Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Rate
Dec 11We Think Moleculin Biotech (NASDAQ:MBRX) Can Afford To Drive Business Growth
Aug 18Moleculin Biotech to join Russell 2000 Index
Jun 15Is Moleculin Biotech (NASDAQ:MBRX) In A Good Position To Invest In Growth?
May 04Moleculin shares soar after promising Annamycin pre-clinical readout
Feb 02Moleculin Biotech under pressure on reverse stock split
Jan 29Here's Why We're A Bit Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation
Jan 15Moleculin Bio's Annamycin an Orphan Drug in U.S. for soft tissue sarcomas
Dec 29Moleculin Bio on go with mid-stage study of Annamycin for lung metastases
Dec 17Moleculin Biotech's annamycin shows encouraging action in animal study
Nov 19Moleculin Biotech EPS beats by $0.04
Nov 13Moleculin further collaborates to advance WP1122 in COVID-19
Oct 29Shareholder Returns
MBRX | US Biotechs | US Market | |
---|---|---|---|
7D | -0.4% | 0.4% | 1.0% |
1Y | -58.7% | 0.9% | 21.9% |
Return vs Industry: MBRX underperformed the US Biotechs industry which returned 0.9% over the past year.
Return vs Market: MBRX underperformed the US Market which returned 21.9% over the past year.
Price Volatility
MBRX volatility | |
---|---|
MBRX Average Weekly Movement | 13.8% |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.8% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MBRX's share price has been volatile over the past 3 months.
Volatility Over Time: MBRX's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2015 | 18 | Wally Klemp | moleculin.com |
Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers.
Moleculin Biotech, Inc. Fundamentals Summary
MBRX fundamental statistics | |
---|---|
Market cap | US$10.31m |
Earnings (TTM) | -US$29.77m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.3x
P/E RatioIs MBRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MBRX income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$29.77m |
Earnings | -US$29.77m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -13.36 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did MBRX perform over the long term?
See historical performance and comparison